Form 4: DarioHealth Director Adam Stern Acquires Series-C Preferred Stock

Adam Stern, a director of DarioHealth Corp., reports the acquisition of Series-C Preferred Stock convertible into common stock, along with indirect ownership of common stock through AKS Family Partnership, L.P.

Summary

• On February 15, 2024, Adam Stern, a director of DarioHealth Corp., acquired Series-C Preferred Stock.
• The Series-C Preferred Stock is convertible into common stock at a price of $2.02 per share.
• The conversion will occur either 15 months after the effective date of the certificate of designation or upon consent of holders of at least 50.1% of the outstanding shares.
• Stern also indirectly owns common stock through AKS Family Partnership, L.P.
• The reporting person has beneficial ownership limitations provided for in the offering documents relating to the sale of the Series-C Preferred Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing reporting a transaction. The director's investment could be seen as a positive signal, but it's not overwhelmingly positive.

Positives

• A director's investment in Series-C Preferred Stock could signal confidence in the company's future prospects.

Future Outlook

The Series-C Preferred Stock will convert into common stock either 15 months after the effective date or upon consent of holders of at least 50.1% of the outstanding shares.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the healthcare technology industry. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• Shareholders may view the director's purchase of Series-C Preferred Stock as a positive sign.

Key Dates